Clinical Trial Update: Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study [Phase 1, Phase 2]

View source ↗

Summary

A Phase Ib/II study evaluating lisatoclax in combination with standard regimens R-CHOP or Pola-R-CHP for untreated diffuse large B-cell lymphoma; the trial is n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Lisatoclax (lisatoclax)
• Rituximab (rituximab)
• polatuzumab vedotin (polatuzumab vedotin)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING